Catalyst Pharmaceutical
CPRX
105 hedge funds and large institutions have $219M invested in Catalyst Pharmaceutical in 2017 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 30 increasing their positions, 21 reducing their positions, and 13 closing their positions.
192% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 13
144% more capital invested
Capital invested by funds: $89.7M → $219M (+$129M)
43% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 21
31% more funds holding
Funds holding: 80 → 105 (+25)
12.6% more ownership
Funds ownership: 42.11% → 54.7% (+13%)
16% less call options, than puts
Call options by funds: $108K | Put options by funds: $128K
Top Buyers
| 1 |
CCM
Consonance Capital Management
New York
|
+$13.6M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.6M |
| 3 |
Millennium Management
New York
|
+$6.83M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$4.53M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$4.07M |
Top Sellers
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$2.46M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.41M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$1.22M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.21M |
| 5 |
JP Morgan Chase
New York
|
-$273K |
CPRX Hedge Fund Activity: Q4 2017 in Review
105 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2017, worth a combined $219M — up 144% from $89.7M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new CPRX positions and 13 closed out — a net gain of 25 holders — while 30 added to existing stakes and 21 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $13.6M. The largest seller was Avoro Capital Advisors, cutting an estimated $2.46M.
- 105 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2017, up from 80 in Q3 2017.
- Funds reported $219M of Catalyst Pharmaceutical stock for Q4 2017, up 144% quarter-over-quarter.
- 38 funds opened new Catalyst Pharmaceutical positions in Q4 2017 and 13 closed out, a net change of +25 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2017 was Consonance Capital Management, an estimated $13.6M added.
- The largest Catalyst Pharmaceutical seller in Q4 2017 was Avoro Capital Advisors, an estimated $2.46M sold.
Based on aggregated 13F filings for Q4 2017.